Crizotinib

Generic Name: Crizotinib

Brand Names: Xalkori

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₂Cl_₂FN_₅O

CAS Number: 877399-52-5

Unique Ingredient Identifier: 53AH36668S

Background: Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusio...

Indication: Crizotinib is a kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test. Crizotinib is also indicated for the treatment of relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK...

Associated Conditions: Metastatic Non-Small Cell Lung Cancer, Refractory Anaplastic Large Cell Lymphoma, Recurrent Inflammatory Myofibroblastic Tumors, Refractory Inflammatory Myofibroblastic Tumors, Relapsed Anaplastic Large Cell Lymphoma, Unresectable Inflammatory Myofibroblastic Tumors

Associated Therapies: -

Clinical Trials

Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)

Phase 1

Terminated

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Avelumab
Drug: Crizotinib
Drug: PF-06463922

First Posted Date: 2015-10-22

Last Posted Date: 2023-07-07

Lead Sponsor: Pfizer

Target Recruit Count: 43

Registration Number: NCT02584634

Locations: 🇺🇸
Ophthalmic Consultants of Boston Inc (OCB), Boston, Massachusetts, United States
🇯🇵
Aichi cancer center central hospital, Nagoya, Aichi, Japan
🇪🇸
Hospital Universitari de la Vall d'Hebron, Barcelona, Spain

and more 17 locations

A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 1

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Bevacizumab
Drug: Nivolumab
Other: Best Supportive Care
Drug: Erlotinib
Drug: Crizotinib
Drug: Pemetrexed
Drug: nab-Paclitaxel
Drug: Paclitaxel
Drug: Docetaxel
Drug: Gemcitabine
Drug: Carboplatin

First Posted Date: 2015-10-12

Last Posted Date: 2021-05-06

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 341

Registration Number: NCT02574078

Locations: 🇺🇸
Cancer Care Center, Bismarck, North Dakota, United States
🇺🇸
Lehigh Valley Hospital, Allentown, Pennsylvania, United States
🇺🇸
Texas Oncology Cancer Center - Sugar Land, Sugar Land, Texas, United States

and more 119 locations

Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients

Phase 1

Terminated

Conditions: ALK-positive Advanced NSCLC

Interventions: Drug: Crizotinib
Drug: Pembrolizumab

First Posted Date: 2015-07-29

Last Posted Date: 2019-07-01

Lead Sponsor: Pfizer

Target Recruit Count: 9

Registration Number: NCT02511184

Locations: 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States

and more 11 locations

Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS)

Phase 2

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: Crizotinib

First Posted Date: 2015-07-16

Last Posted Date: 2017-10-25

Lead Sponsor: Fondazione Ricerca Traslazionale

Target Recruit Count: 80

Registration Number: NCT02499614

Locations: 🇮🇹
Ospedale per gli Infermi - Presidio Ospedaliero di Faenza- Unità Operativa di Oncologia Medica, Faenza, Ravenna, Italy
🇮🇹
Ospedale Umberto I°- Unità Operativa di Oncologia, Lugo, Ravenna, Italy
🇮🇹
IRCCS A.O.U. San Martino- IST- Istituto Nazionale per la Ricerca sul Cancro- U.O.S. Tumori Polmonari, Genova, Italy

and more 23 locations

A Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib

Phase 4

Withdrawn

Conditions: Systemic Anaplastic Large-Cell Lymphoma

Interventions: Drug: crizotinib

First Posted Date: 2015-07-01

Last Posted Date: 2016-12-30

Lead Sponsor: Jun Zhu

Registration Number: NCT02487316

Locations: 🇨🇳
Weiping Liu, Beijing, Beijing, China

Crizotinib (Xalkori) Expanded Access Protocol For The Treatment Of Adult Or Pediatric Patients

Conditions: Neoplasm

First Posted Date: 2015-06-16

Last Posted Date: 2024-06-26

Lead Sponsor: Pfizer

Registration Number: NCT02473497

Locations: 🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸
Johns Hopkins All Children's Hospital, Saint Petersburg, Florida, United States

and more 13 locations

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2

Active, not recruiting

Conditions: Advanced Malignant Solid Neoplasm
Breast Carcinoma
Cervical Carcinoma
Liver Carcinoma
Malignant Uterine Neoplasm
Recurrent Gastric Carcinoma
Recurrent Head and Neck Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Prostate Carcinoma
Recurrent Rectal Carcinoma

Interventions: Drug: Afatinib
Drug: Capivasertib
Drug: Binimetinib
Drug: Adavosertib
Procedure: Biospecimen Collection
Other: Cytology Specimen Collection Procedure
Drug: Afatinib Dimaleate
Drug: Dabrafenib
Drug: Defactinib
Drug: Fexagratinib
Drug: Dasatinib
Drug: Ipatasertib
Procedure: Biopsy
Drug: Crizotinib
Drug: Dabrafenib Mesylate
Drug: Taselisib
Drug: Sapanisertib
Drug: PI3K-beta Inhibitor GSK2636771
Drug: Defactinib Hydrochloride
Drug: Palbociclib
Biological: Nivolumab
Drug: Copanlisib
Drug: Ulixertinib
Biological: Trastuzumab Emtansine
Drug: Copanlisib Hydrochloride
Biological: Relatlimab
Procedure: Computed Tomography
Drug: Trametinib
Biological: Pertuzumab
Drug: Erdafitinib
Procedure: Radiologic Examination
Procedure: Multigated Acquisition Scan
Drug: Larotrectinib
Procedure: Echocardiography
Drug: Osimertinib
Biological: Trastuzumab
Drug: Larotrectinib Sulfate
Other: Laboratory Biomarker Analysis
Procedure: Magnetic Resonance Imaging
Drug: Vismodegib
Drug: Sunitinib Malate
Procedure: Radionuclide Imaging

First Posted Date: 2015-06-08

Last Posted Date: 2024-12-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 6452

Registration Number: NCT02465060

Locations: 🇺🇸
Alaska Women's Cancer Care, Anchorage, Alaska, United States
🇺🇸
Anchorage Oncology Centre, Anchorage, Alaska, United States
🇺🇸
Katmai Oncology Group, Anchorage, Alaska, United States

and more 1416 locations

A Pilot Study of Crizotinib in Patients With c-MET Positive Gastric Adenocarcinoma as a Third-line Chemotherapy

Phase 2

Completed

Conditions: c-MET Positive Gastric Cancer

Interventions: Drug: crizotinib

First Posted Date: 2015-05-06

Last Posted Date: 2017-02-17

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 2

Registration Number: NCT02435108

Locations: 🇰🇷
Samsung Medical center, Seoul, Korea, Republic of

Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas

Phase 2

Completed

Conditions: Anaplastic Large Cell Lymphoma, ALK-Positive

Interventions: Drug: crizotinib

First Posted Date: 2015-04-17

Last Posted Date: 2023-03-06

Lead Sponsor: University of Milano Bicocca

Target Recruit Count: 12

Registration Number: NCT02419287

Locations: 🇮🇹
ASST-Monza, Monza, Italy/MB, Italy

Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations

Early Phase 1

Withdrawn

Conditions: Non-Small Cell Lung Cancer

Interventions: Radiation: PET-Adaptive RT
Drug: Erlotinib
Drug: Crizotinib

First Posted Date: 2014-10-29

Last Posted Date: 2016-06-24

Lead Sponsor: University of Michigan Rogel Cancer Center

Registration Number: NCT02277457

Locations: 🇺🇸
University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy